Do analysts rate GNS or DPH?

Genus presently has a consensus price target of GBX 3,216.67, indicating a potential upside of 51.02%. Given Genus' stronger consensus rating and higher probable upside, research analysts clearly believe Genus is more favorable than Dechra Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Genus 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Dechra Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better valuation & earnings, GNS or HWDN?

Howden Joinery Group has higher revenue and earnings than Genus. Howden Joinery Group is trading at a lower price-to-earnings ratio than Genus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Genus £672M 2.11 £7.87M £71.00 30.00 Howden Joinery Group £2.42B 1.82 £253.42M £49.00 16.34

Does the media favor GNS or HWDN?

In the previous week, Howden Joinery Group had 2 more articles in the media than Genus. MarketBeat recorded 5 mentions for Howden Joinery Group and 3 mentions for Genus. Howden Joinery Group's average media sentiment score of 1.09 beat Genus' score of 0.37 indicating that Howden Joinery Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Genus 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Howden Joinery Group 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate GNS or CTY?

Genus currently has a consensus price target of GBX 3,216.67, indicating a potential upside of 51.02%. Given Genus' stronger consensus rating and higher possible upside, research analysts clearly believe Genus is more favorable than City of London. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Genus 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 City of London 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher earnings & valuation, GNS or CTY?

City of London has lower revenue, but higher earnings than Genus. City of London is trading at a lower price-to-earnings ratio than Genus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Genus £672M 2.11 £7.87M £71.00 30.00 City of London £568.96M 5.28 £294.08M £113.99 5.12

Is GNS or CTY more profitable?

City of London has a net margin of 97.40% compared to Genus' net margin of 7.07%. City of London's return on equity of 22.92% beat Genus' return on equity. Company Net Margins Return on Equity Return on Assets Genus 7.07% 9.70% 3.31% City of London 97.40% 22.92% 4.00%

Does the media refer more to GNS or CTY?

In the previous week, City of London had 2 more articles in the media than Genus. MarketBeat recorded 5 mentions for City of London and 3 mentions for Genus. Genus' average media sentiment score of 0.37 beat City of London's score of 0.10 indicating that Genus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Genus 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral City of London 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings and valuation, GNS or SMWH?

WH Smith has higher revenue and earnings than Genus. WH Smith is trading at a lower price-to-earnings ratio than Genus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Genus £672M 2.11 £7.87M £71.00 30.00 WH Smith £1.59B 0.39 £63.01M -£96.70 N/A

Is GNS or SMWH more profitable?

Genus has a net margin of 7.07% compared to WH Smith's net margin of -9.48%. Genus' return on equity of 9.70% beat WH Smith's return on equity. Company Net Margins Return on Equity Return on Assets Genus 7.07% 9.70% 3.31% WH Smith -9.48% -90.46% 6.62%

Does the media favor GNS or SMWH?

In the previous week, Genus and Genus both had 3 articles in the media. WH Smith's average media sentiment score of 0.58 beat Genus' score of 0.37 indicating that WH Smith is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Genus 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral WH Smith 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, CPG or GNS?

Compass Group has higher revenue and earnings than Genus. Compass Group is trading at a lower price-to-earnings ratio than Genus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Compass Group £48.49B 0.01 £1.35B £118.70 0.26 Genus £672M 2.11 £7.87M £71.00 30.00

Does the media refer more to CPG or GNS?

In the previous week, Genus had 2 more articles in the media than Compass Group. MarketBeat recorded 3 mentions for Genus and 1 mentions for Compass Group. Genus' average media sentiment score of 0.37 beat Compass Group's score of 0.00 indicating that Genus is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Compass Group 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Genus 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Genus (GNS) Competitors

GBX 2,130 -44.00 (-2.02%)

As of 07/17/2026 12:18 PM Eastern

Compare

GNS vs. DPH, HWDN, CTY, SMWH, and CPG

Should you buy Genus stock or one of its competitors? MarketBeat compares Genus with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Genus include Dechra Pharmaceuticals (DPH), Howden Joinery Group (HWDN), City of London (CTY), WH Smith (SMWH), and Compass Group (CPG). These companies are all part of the "personal services" industry.

How does Genus compare to Dechra Pharmaceuticals?

Genus (LON:GNS) and Dechra Pharmaceuticals (LON:DPH) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, institutional ownership, analyst recommendations, risk, profitability and earnings.

Genus presently has a consensus price target of GBX 3,216.67, indicating a potential upside of 51.02%. Given Genus' stronger consensus rating and higher probable upside, research analysts clearly believe Genus is more favorable than Dechra Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genus	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Dechra Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Genus had 3 more articles in the media than Dechra Pharmaceuticals. MarketBeat recorded 3 mentions for Genus and 0 mentions for Dechra Pharmaceuticals. Genus' average media sentiment score of 0.37 beat Dechra Pharmaceuticals' score of 0.00 indicating that Genus is being referred to more favorably in the media.

Company	Overall Sentiment
Genus	Neutral
Dechra Pharmaceuticals	Neutral

Genus pays an annual dividend of GBX 32 per share and has a dividend yield of 1.5%. Dechra Pharmaceuticals pays an annual dividend of GBX 45 per share. Genus pays out 45.1% of its earnings in the form of a dividend. Dechra Pharmaceuticals pays out -18,000.0% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Genus has a beta of 0.901, meaning that its stock price is 10% less volatile than the broader market. Comparatively, Dechra Pharmaceuticals has a beta of 0.78, meaning that its stock price is 22% less volatile than the broader market.

52.2% of Genus shares are owned by institutional investors. Comparatively, 105.5% of Dechra Pharmaceuticals shares are owned by institutional investors. 0.7% of Genus shares are owned by insiders. Comparatively, 9.3% of Dechra Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Genus has higher earnings, but lower revenue than Dechra Pharmaceuticals. Dechra Pharmaceuticals is trading at a lower price-to-earnings ratio than Genus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genus	£672M	2.11	£7.87M	£71.00	30.00
Dechra Pharmaceuticals	£761.50M	0.00	-£27.90M	-£0.25	N/A

Genus has a net margin of 7.07% compared to Dechra Pharmaceuticals' net margin of -3.66%. Genus' return on equity of 9.70% beat Dechra Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genus	7.07%	9.70%	3.31%
Dechra Pharmaceuticals	-3.66%	-3.92%	0.75%

Summary

Genus beats Dechra Pharmaceuticals on 13 of the 17 factors compared between the two stocks.

How does Genus compare to Howden Joinery Group?

Genus (LON:GNS) and Howden Joinery Group (LON:HWDN) are both personal services companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, profitability, valuation, earnings, risk and dividends.

In the previous week, Howden Joinery Group had 2 more articles in the media than Genus. MarketBeat recorded 5 mentions for Howden Joinery Group and 3 mentions for Genus. Howden Joinery Group's average media sentiment score of 1.09 beat Genus' score of 0.37 indicating that Howden Joinery Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genus	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Howden Joinery Group	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Genus has a beta of 0.901, indicating that its stock price is 10% less volatile than the broader market. Comparatively, Howden Joinery Group has a beta of 1.302, indicating that its stock price is 30% more volatile than the broader market.

52.2% of Genus shares are held by institutional investors. Comparatively, 67.4% of Howden Joinery Group shares are held by institutional investors. 0.7% of Genus shares are held by company insiders. Comparatively, 1.0% of Howden Joinery Group shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Howden Joinery Group has higher revenue and earnings than Genus. Howden Joinery Group is trading at a lower price-to-earnings ratio than Genus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genus	£672M	2.11	£7.87M	£71.00	30.00
Howden Joinery Group	£2.42B	1.82	£253.42M	£49.00	16.34

Genus currently has a consensus price target of GBX 3,216.67, suggesting a potential upside of 51.02%. Howden Joinery Group has a consensus price target of GBX 993.17, suggesting a potential upside of 24.07%. Given Genus' stronger consensus rating and higher possible upside, equities analysts clearly believe Genus is more favorable than Howden Joinery Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genus	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Howden Joinery Group	0 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Howden Joinery Group has a net margin of 11.07% compared to Genus' net margin of 7.07%. Howden Joinery Group's return on equity of 23.58% beat Genus' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genus	7.07%	9.70%	3.31%
Howden Joinery Group	11.07%	23.58%	10.70%

Genus pays an annual dividend of GBX 32 per share and has a dividend yield of 1.5%. Howden Joinery Group pays an annual dividend of GBX 21.30 per share and has a dividend yield of 2.7%. Genus pays out 45.1% of its earnings in the form of a dividend. Howden Joinery Group pays out 43.5% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Howden Joinery Group is clearly the better dividend stock, given its higher yield and lower payout ratio.

Summary

Howden Joinery Group beats Genus on 12 of the 18 factors compared between the two stocks.

How does Genus compare to City of London?

Genus (LON:GNS) and City of London (LON:CTY) are both personal services companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, institutional ownership, earnings, analyst recommendations, profitability and valuation.

52.2% of Genus shares are owned by institutional investors. Comparatively, 8.7% of City of London shares are owned by institutional investors. 0.7% of Genus shares are owned by insiders. Comparatively, 0.1% of City of London shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Genus pays an annual dividend of GBX 32 per share and has a dividend yield of 1.5%. City of London pays an annual dividend of GBX 21.45 per share and has a dividend yield of 3.7%. Genus pays out 45.1% of its earnings in the form of a dividend. City of London pays out 18.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. City of London is clearly the better dividend stock, given its higher yield and lower payout ratio.

Genus has a beta of 0.901, indicating that its stock price is 10% less volatile than the broader market. Comparatively, City of London has a beta of 0.502, indicating that its stock price is 50% less volatile than the broader market.

City of London has a net margin of 97.40% compared to Genus' net margin of 7.07%. City of London's return on equity of 22.92% beat Genus' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genus	7.07%	9.70%	3.31%
City of London	97.40%	22.92%	4.00%

In the previous week, City of London had 2 more articles in the media than Genus. MarketBeat recorded 5 mentions for City of London and 3 mentions for Genus. Genus' average media sentiment score of 0.37 beat City of London's score of 0.10 indicating that Genus is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genus	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
City of London	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Genus currently has a consensus price target of GBX 3,216.67, indicating a potential upside of 51.02%. Given Genus' stronger consensus rating and higher possible upside, research analysts clearly believe Genus is more favorable than City of London.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genus	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
City of London	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

City of London has lower revenue, but higher earnings than Genus. City of London is trading at a lower price-to-earnings ratio than Genus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genus	£672M	2.11	£7.87M	£71.00	30.00
City of London	£568.96M	5.28	£294.08M	£113.99	5.12

Summary

Genus and City of London tied by winning 9 of the 18 factors compared between the two stocks.

How does Genus compare to WH Smith?

Genus (LON:GNS) and WH Smith (LON:SMWH) are both small-cap personal services companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, media sentiment, profitability, valuation, institutional ownership, dividends, risk and analyst recommendations.

Genus has a net margin of 7.07% compared to WH Smith's net margin of -9.48%. Genus' return on equity of 9.70% beat WH Smith's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genus	7.07%	9.70%	3.31%
WH Smith	-9.48%	-90.46%	6.62%

Genus has a beta of 0.901, suggesting that its stock price is 10% less volatile than the broader market. Comparatively, WH Smith has a beta of 0.922, suggesting that its stock price is 8% less volatile than the broader market.

52.2% of Genus shares are held by institutional investors. Comparatively, 71.9% of WH Smith shares are held by institutional investors. 0.7% of Genus shares are held by insiders. Comparatively, 0.9% of WH Smith shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

WH Smith has higher revenue and earnings than Genus. WH Smith is trading at a lower price-to-earnings ratio than Genus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genus	£672M	2.11	£7.87M	£71.00	30.00
WH Smith	£1.59B	0.39	£63.01M	-£96.70	N/A

In the previous week, Genus and Genus both had 3 articles in the media. WH Smith's average media sentiment score of 0.58 beat Genus' score of 0.37 indicating that WH Smith is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genus	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
WH Smith	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Genus currently has a consensus target price of GBX 3,216.67, suggesting a potential upside of 51.02%. WH Smith has a consensus target price of GBX 570, suggesting a potential upside of 39.49%. Given Genus' stronger consensus rating and higher probable upside, analysts plainly believe Genus is more favorable than WH Smith.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genus	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
WH Smith	0 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.43

Genus pays an annual dividend of GBX 32 per share and has a dividend yield of 1.5%. WH Smith pays an annual dividend of GBX 17.30 per share and has a dividend yield of 4.2%. Genus pays out 45.1% of its earnings in the form of a dividend. WH Smith pays out -17.9% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. WH Smith is clearly the better dividend stock, given its higher yield and lower payout ratio.

Summary

WH Smith beats Genus on 9 of the 16 factors compared between the two stocks.

How does Genus compare to Compass Group?

Compass Group (LON:CPG) and Genus (LON:GNS) are both small-cap personal services companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, media sentiment, dividends, institutional ownership, risk, valuation, analyst recommendations and earnings.

68.2% of Compass Group shares are held by institutional investors. Comparatively, 52.2% of Genus shares are held by institutional investors. 0.5% of Compass Group shares are held by insiders. Comparatively, 0.7% of Genus shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Genus has a net margin of 7.07% compared to Compass Group's net margin of 4.20%. Compass Group's return on equity of 26.12% beat Genus' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Compass Group	4.20%	26.12%	7.52%
Genus	7.07%	9.70%	3.31%

Compass Group has a beta of 0.654, meaning that its share price is 35% less volatile than the broader market. Comparatively, Genus has a beta of 0.901, meaning that its share price is 10% less volatile than the broader market.

Compass Group pays an annual dividend of GBX 66.38 per share and has a dividend yield of 211.2%. Genus pays an annual dividend of GBX 32 per share and has a dividend yield of 1.5%. Compass Group pays out 55.9% of its earnings in the form of a dividend. Genus pays out 45.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Compass Group currently has a consensus price target of GBX 2,932.50, indicating a potential upside of 9,232.04%. Genus has a consensus price target of GBX 3,216.67, indicating a potential upside of 51.02%. Given Compass Group's higher probable upside, equities research analysts clearly believe Compass Group is more favorable than Genus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Compass Group	0 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	3.00
Genus	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

Compass Group has higher revenue and earnings than Genus. Compass Group is trading at a lower price-to-earnings ratio than Genus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Compass Group	£48.49B	0.01	£1.35B	£118.70	0.26
Genus	£672M	2.11	£7.87M	£71.00	30.00

In the previous week, Genus had 2 more articles in the media than Compass Group. MarketBeat recorded 3 mentions for Genus and 1 mentions for Compass Group. Genus' average media sentiment score of 0.37 beat Compass Group's score of 0.00 indicating that Genus is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Compass Group	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Genus	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Compass Group beats Genus on 9 of the 17 factors compared between the two stocks.

Get Genus News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GNS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GNS vs. The Competition

Export

Metric	Genus	Biotechnology Industry	Medical Sector	LON Exchange
Market Cap	£1.41B	£433.86M	£7.01B	£2.57B
Dividend Yield	1.56%	3.90%	2.67%	6.15%
P/E Ratio	30.00	3.48	27.28	368.19
Price / Sales	2.11	6,483.71	527.75	84,555.41
Price / Cash	50.56	13.13	29.05	27.89
Price / Book	2.57	87.30	10.70	7.53
Net Income	£7.87M	-£96.07M	£3.59B	£5.89B
7 Day Performance	5.45%	-2.14%	-2.20%	5.77%
1 Month Performance	-3.45%	1.11%	1.63%	4.95%
1 Year Performance	-11.25%	56.52%	25.64%	61.88%

Genus Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GNS Genus	3.6979 of 5 stars	GBX 2,130 -2.0%	GBX 3,216.67 +51.0%	-11.3%	£1.41B	£672M	30.00	480	Analyst Forecast Gap Up
DPH Dechra Pharmaceuticals	N/A	N/A	N/A	N/A	£4.40B	£761.50M	N/A	2,457
HWDN Howden Joinery Group	4.169 of 5 stars	GBX 796.50 +0.3%	GBX 993.17 +24.7%	-3.6%	£4.38B	£2.42B	16.26	12,000	News Coverage
CTY City of London	N/A	GBX 575 flat	N/A	+17.7%	£2.96B	£568.96M	5.04	N/A
SMWH WH Smith	3.8758 of 5 stars	GBX 397 -0.3%	GBX 570 +43.6%	-61.6%	£597.49M	£1.59B	N/A	14,935

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:GNS) was last updated on 7/19/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Genus (GNS) Competitors

GNS vs. DPH, HWDN, CTY, SMWH, and CPG

How does Genus compare to Dechra Pharmaceuticals?

Summary

How does Genus compare to Howden Joinery Group?

Summary

How does Genus compare to City of London?

Summary

How does Genus compare to WH Smith?

Summary

How does Genus compare to Compass Group?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GNS vs. The Competition

Genus Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Genus (GNS) Competitors

GNS vs. DPH, HWDN, CTY, SMWH, and CPG

How does Genus compare to Dechra Pharmaceuticals?

Do analysts rate GNS or DPH?

Does the media prefer GNS or DPH?

Is GNS or DPH a better dividend stock?

Which has more volatility & risk, GNS or DPH?

Do institutionals & insiders believe in GNS or DPH?

Which has higher valuation and earnings, GNS or DPH?

Is GNS or DPH more profitable?

Summary

How does Genus compare to Howden Joinery Group?

Does the media favor GNS or HWDN?

Which has more volatility and risk, GNS or HWDN?

Do insiders & institutionals have more ownership in GNS or HWDN?

Which has better valuation & earnings, GNS or HWDN?

Do analysts rate GNS or HWDN?

Is GNS or HWDN more profitable?

Is GNS or HWDN a better dividend stock?

Summary

How does Genus compare to City of London?

Do institutionals & insiders have more ownership in GNS or CTY?

Is GNS or CTY a better dividend stock?

Which has more risk and volatility, GNS or CTY?

Is GNS or CTY more profitable?

Does the media refer more to GNS or CTY?

Do analysts rate GNS or CTY?

Which has higher earnings & valuation, GNS or CTY?

Summary

How does Genus compare to WH Smith?

Is GNS or SMWH more profitable?

Which has more risk & volatility, GNS or SMWH?

Do insiders & institutionals have more ownership in GNS or SMWH?

Which has higher earnings and valuation, GNS or SMWH?

Does the media favor GNS or SMWH?

Do analysts prefer GNS or SMWH?

Is GNS or SMWH a better dividend stock?

Summary

How does Genus compare to Compass Group?

Do institutionals and insiders hold more shares of CPG or GNS?

Is CPG or GNS more profitable?

Which has more volatility and risk, CPG or GNS?

Is CPG or GNS a better dividend stock?

Do analysts prefer CPG or GNS?

Which has stronger earnings & valuation, CPG or GNS?

Does the media refer more to CPG or GNS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GNS vs. The Competition

Genus Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools